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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A89of cytokines such as IL-6. From the liver CRP is transported back to the
inﬂamed tissue where it binds its receptors and thereby accumulated by
the tissue. These fragments are released from the tissue as MMPs are
upregulated in response to pro-inﬂammatory induction. C3M is a bio-
marker of type II collagen remodeling,which is released from the synovial
membranewith inducedwithpro-inﬂammatorycytokines. The aimof the
studywas to investigatewhether the level of theproteinﬁngerprintCRPM
together with the tissue turnover biomarker C3M could segregate OA
patients with and without inﬂammatory arthritis.
Methods: CRPM and C3M were measured in the serum of knee OA
patients taking part of the two phase III RCTs (NCT00486434 and
NCT00704847). Baseline and 2 year follow-up pain questionnaires and
radiography were recorded for each patient. An array of additional bio-
markers were measure; C1M, C2M, CTX-II, CTX-I and osteocalcin. The
biomarkers were plotted against each other (ﬁgure) and cut-offs were set
based on reference value and difference between clinical measures and
biomarkers in the two patient groups were analyzed by Mann-Whitney.
Results: Patients were separated into 2 groups; 1) patient with low
CRPM and low C3M, and 2) patients with either high CRPM or high C3M,
or with both high. 16% of the patients were found group 2. Several of the
measures were higher in group 2: Cartilage degradation (C2M) and
connective tissue degradation (C1M) were signiﬁcantly higher
(p¼0.0037, p<0.0001, respectively), as well as WOMAC subscale ques-
tion Q5 (p¼0.0191). There was no group difference in KL score or JSW
nor in CTX-I, CTX-II and osteocalcin. Group 1 patients (low in both CRPM
and C3M) progressed structurally more group 1 patients (p¼0.046).
Conclusions:We found that different of the two inﬂammatory markers
could facilitate patient segregation. This may have many implications,
however most importantly in the identiﬁcation of more OA patients
with the right diagnosis, inﬂammatory vs. non-inﬂammatory disease,
which may beneﬁt from a given treatment.117
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Purpose: Osteoarthritis (OA) is a very common degenerative disease
affecting the articular cartilage in both human and veterinary
medicine.
While conventional treatments like physiotherapy or drugs offer tem-
porary relief of clinical symptoms, restoration of normal cartilage
function has been difﬁcult to achieve. Moreover, in severe cases of
osteoarthritis total articular replacement may be required.
The regenerative medicine offers exciting possibilities for treating OA.
The mesenchymal stem cells are candidates for use in this pathology
because they offer exciting possibilities to differentiate into other tissue
lineages, and have signiﬁcant effects on regeneration and/or main-
tenance of articular cartilage, reducing pain and increasing the articular
functionality.
The aim of this studywas to evaluate the effectiveness of the application
of mesenchymal stem cells derived from inguinal adipose tissue (aMSC)
in the treatment of degenerative joint disease in the elbow, hip and
knee of the canine species.
Methods: This was a serial clinical multi-center study that included a
total of 26 healthy dogs weighting more than 15 kg, with OA docu-
mented by X-Rays and clinical ﬁndings. The joints affected were dis-
tributed in 17 hips, 4 knees and 5 elbows.
The dogs were treated with one 2 ml intra-articular injection of aMSCs
containing 30 millions of aMSC obtained by Dog-Stem® method, fol-
lowing conventional protocol for all joints.
The variables evaluated were a radiological assessment of the affected
joints (mild, moderate or severe), functional limitation (measurement
scale: 0 to 23 points), and joint mobility (measurement scale: 0 to 7
points), as well as serum hyaluronic acid (HA) and collagen type II
cleavage neoepitope (C2C) concentration.
In addition, owners completed a questionnaire on satisfaction with
treatment and the perception of pain in their pets with a visual ana-
logue scale (VAS).
All these variables were measured at baseline (just before applying the
treatment) and one, three and six months after treatment.
Results: The average age and weight of the patients were 58±40
months (age range: 8-135 months), and 35,1±14,0 kg (weigh range:
18,1-66,2 kg), respectively. There were 17 males and 9 females, 10 of
them were spayed.
The radiographic grade of OA remained constant over time.
With respect to other parameters like functional limitation, joint
mobility, owner satisfaction, VAS and serum C2C and HA (Figure 1 and
2, respectively), there was improvement from the ﬁrst month to six
months after treatment. No adverse effects were observed during the
study.
Conclusions: The application of a single intra-articular injection of
aMSCs, demonstrate improvement of the clinical signs and symptoms
of OA, decreasing pain and improving joint function with no adverse
effects and no radiographic changes, with an increase in HA and a
decrease in the C2C serum levels. Stem cells are established as a safe
and promising therapeutic option besides the capacity to regenerate
damaged tissues and organs and there are great expectations for the
future.
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TGFB1 REGULATION AND NOVEL THERAPIES FOR OSTEOARTHRITIS
P. Hopkins. New England Baptist Hosp., Roxbury, MA, USA
Purpose: Exploring the role of biomarkers in osteoarthritis and adhe-
sive capsulitis.
Methods: Pt was a 65 year old wm who presented 6 weeks post total
knee replacement with swelling and limited range of motion. His pre-
vious knee replacement was without complication. His range of motion
was limited to 85 degrees. His blood work showed a normal WBC, ESR,
CRP. His MMP1 and MMP 3 were elevated at 49% and 64% of inﬂam-
matory levels observed in Rheumatoid arthritis.
Results: The patient was placed on doxycyline 100 mg daily. After two
weeks of therapy all swelling had resolved, range of motion had
increased by 50% and pain had completely disappeared. He tolerated
the medication without any adverse events. The dose prescribed was
sub anti microbial.
Conclusions: Osteoarthritis (OA) is the most common form of arthritis,
affecting nearly 27 million people in the United States, and is a chronic
degenerative disorder affecting joint tissue in, e.g., the hands, feet, hips,
knees, or spine. Fibrosis of the surrounding muscle architecture has
been implicated in the development of advanced osteoarthritis.
Doxycycline is a semisynthetic, chemically modiﬁed tetracycline com-
pound that is rapidly absorbed when taken orally and topically, and
which exerts biological effects that are independent of antimicrobial
activity (Greenwald, Ann. N.Y. Acad. Sci., 732: 181-198, 1994).Although a number of investigated therapies against inﬂammatory
conditions, such as OA, have demonstrated palliative properties, these
therapies may not produce consistently beneﬁcial outcomes in subjects.
Therefore, there remains a need for methods to treat subjects with such
inﬂammatory conditions as well as methods to accurately diagnose the
presence of such inﬂammatory conditions in subjects.
Summary of the treatment protocol.
The case report features protocol for treating subjects with inﬂamma-
tory conditions, as well as methods for detecting inﬂammatory con-
ditions. Such inﬂammatory conditions may include, for example, mild
traumatic brain injury (mTBI), also known as concussion, osteoarthritis
(OA), ﬁbromyalgia, diabetic adhesive capsulitis, hypermobility syn-
drome, exercise intolerance, arthropathy, inﬂammatory bowel disease,
constipation, diabetes-associated inﬂammation, adhesion (e.g., post-
operative adhesion, post-operative adhesion after joint replacement
surgery, or abdominal adhesion), Ehlers-Danlos Syndrome, sarcopenia,
sarcoidosis, and liver ﬁbrosis. In various embodiments, the adhesion is
the result of injury, surgery (e.g., joint replacement surgery), or
inﬂammation. In some embodiments, the adhesion occurs in a joint,
tendon, ligament, eye, abdomen, pericardium, or pelvis. In certain
conditions, the joint is a shoulder joint, knee joint, hip joint, ankle joint,
elbow joint, or wrist joint.
We propose that the tetracycline derivatives have a therapeutic role in
treatment of many of the degenerative diseases associated with
inﬂammation, ﬁbrosis, adhesions and subsequent deterioration of the
joint. While historically research in the ﬁeld of degenerative arthritis
has focused on cartilage and bone we hypothesize that the extra-cel-
lural matrix[ECM] and the TGF pathway play a critical role in muscle
sarcopenia and subsequent joint degeneration. Discovery of a bio-
marker for a disease of such widespread catastrophic economic con-
sequence is critical at this time.Biomechanics & Gait
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GAIT CHARACTERISTICS THAT INFLUENCE CARTILAGE THICKNESS
ARE RELATED TO SERUM CONCENTRATIONS OF CARTILAGE
OLIGOMERIC MATRIX PROTEIN BEFORE AND AFTER A
MECHANICAL STIMULUS
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Purpose: The serum concentration of cartilage oligomeric matrix pro-
tein (COMP) has been reported to be elevated in patients with knee
osteoarthritis (OA) and changes in serum COMP concentration due to a
mechanical stimulus (30 minute walk) were associated with cartilage
thinning over ﬁve years. However, it is not clear if there are speciﬁc
features of gait that inﬂuence pre-activity and post-activity COMP lev-
els. While several mechanical measures during walking have been
associated with morphological changes in cartilage, the association
between these mechanical measures and biomarkers in serum remains
unclear. Thus the purpose of this study was to test if speciﬁc gait
characteristics that have been shown to be associated with cartilage
thickness changes are also associated with serum COMP levels before
and after a 30-minutewalk.We tested the hypotheses that the ﬁrst peak
knee adduction moment (KAM), the ﬁrst peak knee ﬂexion moment
(KFM), the knee ﬂexion angle at heel-strike (KFA), and the anterior-
posterior position of the femur relative to the tibia at heel-strike (FP)
were related to baseline levels of COMP in serum as well as COMP levels
in serum 5.5 hours after a mechanical stimulus (mCOMP) in subjects
with and without knee OA.
Methods: An IRB-approved protocol was used to recruit and test 40
healthy subjects and 33 subjects with medial knee OA (Table 1). Blood
was drawn before and 5.5 hours after 30 minutes of walking at a self-
selected normal pace. Serum COMP levels were quantiﬁed using ELISA;
post-activity COMP level was expressed as a percentage of pre-activity
level. Gait mechanics during normal walking at a self-selected speed
were collected using optical motion capture and a ﬂoor-embedded
force plate; kinetic and kinematic measures were calculated using the
point cluster technique and inverse dynamics. Backward stepwise
regressions were used to assess which independent measures of KAM,
KFM, KFA, FP, age, gender, BMI, OA status, and KL grade were
